Non-Alcoholic Fatty Liver Disease Clinical Trials

18 studies are recruiting for non-alcoholic fatty liver disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

New York, New York 6 San Antonio, Texas 5 Boston, Massachusetts 4 Austin, Texas 3 Dallas, Texas 3 Miami, Florida 3 Santa Maria, California 3 Waco, Texas 3

Studies now recruiting

  1. A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

    This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

    Stage
    Phase 3
    Ages
    18 to 75
    Site
    GSK Investigational Site, Arcadia, California
    Locations
    66 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT07221188 on ClinicalTrials.gov

  2. Human Models of Selective Insulin Resistance: Alpelisib, Part I

    The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main questio…

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    Columbia University Irving Medical Center, New York, New York
    Run by
    Columbia University

    See if you can join NCT06354088 on ClinicalTrials.gov

  3. Quantifying Hepatic Mitochondrial Fluxes in Humans

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    Stage
    Phase 4
    Ages
    18 to 80
    Site
    Texas Diabetes Institute - University Health System, San Antonio, Texas
    Locations
    2 in total
    Run by
    The University of Texas Health Science Center at San Antonio

    See if you can join NCT05305287 on ClinicalTrials.gov

  4. InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

    This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The …

    Stage
    Not phased
    Ages
    Any age
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT05463796 on ClinicalTrials.gov

  5. Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help. Objective: To find out how the liver in people with NAFLD responds to feeding, and how this relat…

    Stage
    Phase 2
    Ages
    18 to 100
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    See if you can join NCT03884075 on ClinicalTrials.gov

  6. Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)

    The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abno…

    Stage
    Not phased
    Ages
    18 to 70
    Site
    University of Missouri School of Medicine, Columbia, Missouri
    Run by
    Bettina Mittendorfer

    See if you can join NCT06571474 on ClinicalTrials.gov

  7. Fibrosis Lessens After Metabolic Surgery

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease aff…

    Stage
    Phase 4
    Ages
    18 to 75
    Site
    Cleveland Clinic, Cleveland, Ohio
    Locations
    22 in total
    Run by
    The Cleveland Clinic

    See if you can join NCT06374875 on ClinicalTrials.gov

  8. A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

    Stage
    Phase 3
    Ages
    18 to 75
    Site
    GSK Investigational Site, Chandler, Arizona
    Locations
    91 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT07221227 on ClinicalTrials.gov

  9. A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    GSK Investigational Site, Chandler, Arizona
    Locations
    30 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT06920043 on ClinicalTrials.gov

  10. Effect of Insulin Lowering on Lipogenesis

    The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of …

    Stage
    Phase 1
    Ages
    18 to 65
    Site
    Columbia University Irving Medical Center, New York, New York
    Run by
    Columbia University

    See if you can join NCT07403604 on ClinicalTrials.gov

  11. Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectru…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Pichamol Jirapinyo, MD, MPH

    See if you can join NCT06138821 on ClinicalTrials.gov

  12. A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

    This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    GSK Investigational Site, Rialto, California
    Locations
    3 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT07358546 on ClinicalTrials.gov

  13. Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

    The goal of this observation study is to assess whether endoscopic ultrasound shear wave elastography (EUS-SWE) may be a useful tool for liver fibrosis screening in patients with elevated body mass index and non alcoholic fatty liver disease as compared to other non-invasive screening modalities, w…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Brigham and Women's Hospital

    See if you can join NCT05728697 on ClinicalTrials.gov

  14. Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

    This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the degree of fat in the liver as measured by magnetic resonance imaging.

    Stage
    Not phased
    Ages
    18 to 65
    Site
    Weill Cornell Medicine, New York, New York
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05332613 on ClinicalTrials.gov

  15. Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

    This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

    Stage
    Phase 2
    Ages
    16 to 20
    Site
    Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
    Run by
    Justin Ryder

    See if you can join NCT06355310 on ClinicalTrials.gov

  16. The Olmsted NAFLD Epidemiology Study (TONES)

    Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate models of NAFLD diagnosis and determine long-term outcomes.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Run by
    Mayo Clinic

    See if you can join NCT04365855 on ClinicalTrials.gov

  17. Intermittent Fasting for NAFLD in Adults

    NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI<30kg/m2) is an increasingly recognized condition, sometimes described as "lean NAFLD". Intermittent Fasting (IF) may be uniquely beneficial in non-obese…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Run by
    Massachusetts General Hospital

    See if you can join NCT04899102 on ClinicalTrials.gov

  18. AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

    The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liv…

    Stage
    Not phased
    Ages
    18 and older
    Site
    AdventHealth Translational Research Institute, Orlando, Florida
    Run by
    AdventHealth Translational Research Institute

    See if you can join NCT04807868 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.